Equivalencies: 0 | Classes: 2 | Children: 0 | Explore

Entity

Name
irinotecan
Namespace
CHEBI
Namespace Version
20170511
Namespace URL
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20170511.belns

Appears in Networks 8

Colorectal Cancer Knowledge Assembly - Drugs Pathways and General Biology v1.1.0

Colorectal Cancer Knowledge Assembly with drug associations and Pathways + general CRC biology

Colorectal Cancer Knowledge Assembly - Drugs Pathways v1.0.0

Colorectal Cancer Knowledge Assembly with drug associations and Pathways.

Colorectal Cancer Model v2.0.0

Colorectal Cancer Model

Colorectal Cancer Model v0.0.0

Colorectal Cancer Model

Colorectal Cancer Model v2.0.3

Colorectal Cancer Model

Colorectal Cancer Model v2.0.4

Colorectal Cancer Model, uploaded by reagon

Colorectal Cancer Model v2.0.5

Colorectal Cancer Model, uploaded by reagon

Colorectal Cancer Model v2.0.6

Colorectal Cancer Model, uploaded by reagon

In-Edges 79

path(MESHD:Leukopenia) positiveCorrelation a(CHEBI:irinotecan)

Ad libitum fed animals developed leucopenia compared with untreated controls, whereas fasted mice did not. PubMed:26332723

bp(MESHPP:Fasting) decreases a(CHEBI:irinotecan)

Fasting prevented the diarrhoea and visible signs of discomfort induced by irinotecan. PubMed:26332723

bp(MESHPP:Fasting) causesNoChange a(CHEBI:irinotecan)

Fasting protected against irinotecan-induced side effects without interfering with its anti-tumour efficacy. PubMed:26332723

g(HGNC:UGT1A1) association a(CHEBI:irinotecan)

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

p(HGNC:ABCB1) association a(CHEBI:irinotecan)

Furthermore, miR-451 restoration decreases expression of the ATP-binding cassette drug transporter ABCB1 and results in irinotecan sensitization. PubMed:21948564

Annotations
Experimental Factor Ontology (EFO)
HCT116
MeSH
Peroxisomes
MeSH
Colorectal Neoplasms
Evidence and Conclusion Ontology
immunohistochemistry
Evidence and Conclusion Ontology
protein expression
MeSH
Macrophages
NCBI Taxonomy Names
Homo sapiens
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:"Se-methyl-L-selenocysteine") increases a(CHEBI:irinotecan)

We have previously shown that 5-methylselenocysteine (MSC) enhances therapeutic efficacy of irinotecan in various human tumor xenografts. PubMed:19632930

Annotations
Experimental Factor Ontology (EFO)
MDAMB435
MeSH
Intracellular Space
MeSH
Neoplasms
Evidence and Conclusion Ontology
western blot
MeSH
Heterografts
NCBI Taxonomy Names
Homo sapiens
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

bp(MESHPP:"Drug Resistance") association a(CHEBI:irinotecan)

Primary and metastatic tumors expressing EDR to 5FU + FA demonstrated up to 58% cross-resistance to a variety of chemotherapy agents, with the lowest percentages for oxaliplatin (11% and 8%, respectively) and irinotecan (16% and 14%). PubMed:20695724

Annotations
Experimental Factor Ontology (EFO)
HeLa cell
MeSH
Intracellular Space
MeSH
Neoplasms
Evidence and Conclusion Ontology
RNAi
MeSH
Colon
NCBI Taxonomy Names
Rattus norvegicus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

p(HGNC:STAT3) increases a(CHEBI:irinotecan)

Inhibition of Stat3 by peptide aptamer rS3-PA enhances growth suppressive effects of irinotecan on colorectal cancer cells. PubMed:25436684

Annotations
Experimental Factor Ontology (EFO)
COLO205
MeSH
Chromatin
MeSH
Colorectal Neoplasms
Evidence and Conclusion Ontology
western blot
MeSH
Allografts
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

path(MESHD:"Colorectal Neoplasms") association a(CHEBI:irinotecan)

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

Annotations
Experimental Factor Ontology (EFO)
COLO205
MeSH
Chromatin
MeSH
Colorectal Neoplasms
Evidence and Conclusion Ontology
western blot
MeSH
Allografts
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

bp(MESHPP:Fasting) decreases a(CHEBI:irinotecan)

Fasting prevented the diarrhoea and visible signs of discomfort induced by irinotecan. PubMed:26332723

Annotations
Experimental Factor Ontology (EFO)
LS174T
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Peritoneum
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

bp(MESHPP:Fasting) causesNoChange a(CHEBI:irinotecan)

Fasting protected against irinotecan-induced side effects without interfering with its anti-tumour efficacy. PubMed:26332723

Annotations
Experimental Factor Ontology (EFO)
LS174T
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Plasma
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

g(HGNC:KRAS) causesNoChange a(CHEBI:irinotecan)

In KRAS mutated tumors, median OS was 23.4 months with oxaliplatin-based regimen, and 23.6 months with irinotecan-based regimen, with no significant difference (HR 1.30; 95 % CI 0.81-2.09; P=0.27). In KRAS wild-type tumors, median OS was 30.3 months with oxaliplatin-based regimen, and 25.4 months with irinotecan-based regimen, with no significant difference (HR 0.81; 95 % CI 0.52-1.24; P=0.33). Similarly, KRAS mutational status had no significant effect on efficacy of oxaliplatin or irinotecan regarding PFS. PubMed:27155924

a(MESHC:"technetium 99m HYNIC-duramycin") positiveCorrelation a(CHEBI:irinotecan)

In vivo, (99m)Tc-duramycin uptake in COLO205 xenografts was increased 2.3- and 2.8-fold (P < 0.001) in mice treated with irinotecan and combination therapy, respectively. PubMed:26837335

Annotations
Experimental Factor Ontology (EFO)
HCT-15 cell
MeSH
Intracellular Space
MeSH
Condylomata Acuminata
MeSH
Mucus
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

act(p(HGNC:SPARC), ma(tscript)) increases a(CHEBI:irinotecan)

We were able to achieve restoration of their radiosensitivity and sensitivity to 5-fluorouracil and irinotecan by reexpression of SPARC in tumor xenografts. Moreover, treatment of mice with SPARC conferred increased sensitivity to chemotherapy and led to significant regression of xenografted tumors. The results show that modulation of SPARC expression affects colorectal cancer sensitivity to radiation and chemotherapy. SPARC-based gene or protein therapy may ameliorate the emergence of resistant clones and eradicate existing refractory clones and offers a novel approach to treating cancer. PubMed:15902309

Annotations
Experimental Factor Ontology (EFO)
SW480
MeSH
Intracellular Space
MeSH
Neoplasms
MeSH
Mucus
NCBI Taxonomy Names
Crataegus azarolus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

p(HGNC:ACLY) association a(CHEBI:irinotecan)

We conclude that targeting ACLy may improve the therapeutic effects of irinotecan and that simultaneous targeting of ACLy and AKT may be warranted to overcome SN38 resistance. PubMed:24132143

Annotations
Experimental Factor Ontology (EFO)
cancer cell line
MeSH
Microtubules
MeSH
Colorectal Neoplasms
Evidence and Conclusion Ontology
RNAi
MeSH
Heterografts
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

p(HGNC:HGF) decreases a(CHEBI:irinotecan)

We generated xenograft in NOD/SCID mice inoculating HCT-116 human colorectal cancer cells subcutaneously with or without fibroblast. We found that the combination of CPT-11 and anti-HGF antibody induced marked suppression of tumor development. These results suggest that HGF produced by fibroblast induce CPT-11 resistance, and that anti-HGF antibody abrogate such resistance in vivo. fibroblast-derived HGF is important determinant of chemoresistance. Anti-HGF monoclonal antibody treatment confirmed the importance of this growth factor for chemoresistance in CRC PubMed:26090722

path(MESHD:Leukopenia) association a(CHEBI:irinotecan)

Ad libitum fed animals developed leucopenia compared with untreated controls, whereas fasted mice did not. PubMed:26332723

Annotations
Experimental Factor Ontology (EFO)
LS174T
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Peritoneum
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

p(HGNC:AKT1) association a(CHEBI:irinotecan)

and sensitized them to pharmacological treatments with irinotecan, SN-38 and cetuximab (at least in part through a down-regulation of AKT). PubMed:25917796

Annotations
Experimental Factor Ontology (EFO)
Caco-2
Experimental Factor Ontology (EFO)
DLD-1 cell
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Plasma
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

p(HGNC:UBE3D) decreases a(CHEBI:irinotecan)

and sensitized them to pharmacological treatments with irinotecan, SN-38 and cetuximab (at least in part through a down-regulation of AKT). PubMed:25917796

Annotations
Experimental Factor Ontology (EFO)
Caco-2
Experimental Factor Ontology (EFO)
DLD-1 cell
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Plasma
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

bp(MESHPP:"DNA Breaks, Double-Stranded") association a(CHEBI:irinotecan)

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

Annotations
Experimental Factor Ontology (EFO)
COLO205
MeSH
Chromatin
MeSH
Colorectal Neoplasms
Evidence and Conclusion Ontology
western blot
MeSH
Allografts
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

bp(GOBP:"negative regulation of hepatocyte growth factor receptor signaling pathway") association a(CHEBI:irinotecan)

We determined secreted HGF in fibroblast conditioned medium (CM). Combination treatment of anti-HGF antibody and irinotecan (CPT-11) directly enhanced CPT-11 sensitivity in CRC PubMed:26090722

Annotations
Experimental Factor Ontology (EFO)
HT-29
Experimental Factor Ontology (EFO)
DLD1
MeSH
Intracellular Space
MeSH
Gastrointestinal Neoplasms
MeSH
Mucus
NCBI Taxonomy Names
Crataegus azarolus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

bp(GOBP:"apoptotic process") association a(CHEBI:irinotecan)

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

Annotations
Experimental Factor Ontology (EFO)
COLO205
MeSH
Chromatin
MeSH
Colorectal Neoplasms
Evidence and Conclusion Ontology
western blot
MeSH
Allografts
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

g(HGNC:UGT1A1) association a(CHEBI:irinotecan)

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

p(HGNC:ABCB1) association a(CHEBI:irinotecan)

Furthermore, miR-451 restoration decreases expression of the ATP-binding cassette drug transporter ABCB1 and results in irinotecan sensitization. PubMed:21948564

a(CHEBI:"Se-methyl-L-selenocysteine") increases a(CHEBI:irinotecan)

We have previously shown that 5-methylselenocysteine (MSC) enhances therapeutic efficacy of irinotecan in various human tumor xenografts. PubMed:19632930

bp(MESHPP:"Drug Resistance") association a(CHEBI:irinotecan)

Primary and metastatic tumors expressing EDR to 5FU + FA demonstrated up to 58% cross-resistance to a variety of chemotherapy agents, with the lowest percentages for oxaliplatin (11% and 8%, respectively) and irinotecan (16% and 14%). PubMed:20695724

p(HGNC:STAT3) increases a(CHEBI:irinotecan)

Inhibition of Stat3 by peptide aptamer rS3-PA enhances growth suppressive effects of irinotecan on colorectal cancer cells. PubMed:25436684

path(MESHD:"Colorectal Neoplasms") association a(CHEBI:irinotecan)

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

bp(MESHPP:Fasting) decreases a(CHEBI:irinotecan)

Fasting prevented the diarrhoea and visible signs of discomfort induced by irinotecan. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

bp(MESHPP:Fasting) causesNoChange a(CHEBI:irinotecan)

Fasting protected against irinotecan-induced side effects without interfering with its anti-tumour efficacy. PubMed:26332723

Annotations
MeSH
Plasma
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

g(HGNC:KRAS) causesNoChange a(CHEBI:irinotecan)

In KRAS mutated tumors, median OS was 23.4 months with oxaliplatin-based regimen, and 23.6 months with irinotecan-based regimen, with no significant difference (HR 1.30; 95 % CI 0.81-2.09; P=0.27). In KRAS wild-type tumors, median OS was 30.3 months with oxaliplatin-based regimen, and 25.4 months with irinotecan-based regimen, with no significant difference (HR 0.81; 95 % CI 0.52-1.24; P=0.33). Similarly, KRAS mutational status had no significant effect on efficacy of oxaliplatin or irinotecan regarding PFS. PubMed:27155924

a(MESHC:"technetium 99m HYNIC-duramycin") positiveCorrelation a(CHEBI:irinotecan)

In vivo, (99m)Tc-duramycin uptake in COLO205 xenografts was increased 2.3- and 2.8-fold (P < 0.001) in mice treated with irinotecan and combination therapy, respectively. PubMed:26837335

act(p(HGNC:SPARC), ma(tscript)) increases a(CHEBI:irinotecan)

We were able to achieve restoration of their radiosensitivity and sensitivity to 5-fluorouracil and irinotecan by reexpression of SPARC in tumor xenografts. Moreover, treatment of mice with SPARC conferred increased sensitivity to chemotherapy and led to significant regression of xenografted tumors. The results show that modulation of SPARC expression affects colorectal cancer sensitivity to radiation and chemotherapy. SPARC-based gene or protein therapy may ameliorate the emergence of resistant clones and eradicate existing refractory clones and offers a novel approach to treating cancer. PubMed:15902309

p(HGNC:ACLY) association a(CHEBI:irinotecan)

We conclude that targeting ACLy may improve the therapeutic effects of irinotecan and that simultaneous targeting of ACLy and AKT may be warranted to overcome SN38 resistance. PubMed:24132143

p(HGNC:HGF) decreases a(CHEBI:irinotecan)

We generated xenograft in NOD/SCID mice inoculating HCT-116 human colorectal cancer cells subcutaneously with or without fibroblast. We found that the combination of CPT-11 and anti-HGF antibody induced marked suppression of tumor development. These results suggest that HGF produced by fibroblast induce CPT-11 resistance, and that anti-HGF antibody abrogate such resistance in vivo. fibroblast-derived HGF is important determinant of chemoresistance. Anti-HGF monoclonal antibody treatment confirmed the importance of this growth factor for chemoresistance in CRC PubMed:26090722

Annotations
Experimental Factor Ontology (EFO)
HCT 116 cell
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

path(MESHD:Leukopenia) association a(CHEBI:irinotecan)

Ad libitum fed animals developed leucopenia compared with untreated controls, whereas fasted mice did not. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

p(HGNC:AKT1) association a(CHEBI:irinotecan)

and sensitized them to pharmacological treatments with irinotecan, SN-38 and cetuximab (at least in part through a down-regulation of AKT). PubMed:25917796

Annotations
Experimental Factor Ontology (EFO)
Caco-2
Experimental Factor Ontology (EFO)
DLD-1 cell
Disease Ontology (DO)
colorectal cancer

p(HGNC:UBE3D) decreases a(CHEBI:irinotecan)

and sensitized them to pharmacological treatments with irinotecan, SN-38 and cetuximab (at least in part through a down-regulation of AKT). PubMed:25917796

Annotations
Experimental Factor Ontology (EFO)
Caco-2
Experimental Factor Ontology (EFO)
DLD-1 cell
Disease Ontology (DO)
colorectal cancer

bp(MESHPP:"DNA Breaks, Double-Stranded") association a(CHEBI:irinotecan)

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

bp(GOBP:"negative regulation of hepatocyte growth factor receptor signaling pathway") association a(CHEBI:irinotecan)

We determined secreted HGF in fibroblast conditioned medium (CM). Combination treatment of anti-HGF antibody and irinotecan (CPT-11) directly enhanced CPT-11 sensitivity in CRC PubMed:26090722

bp(GOBP:"apoptotic process") association a(CHEBI:irinotecan)

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

g(HGNC:UGT1A1) association a(CHEBI:irinotecan)

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

bp(MESHPP:Fasting) decreases a(CHEBI:irinotecan)

Fasting prevented the diarrhoea and visible signs of discomfort induced by irinotecan. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

bp(MESHPP:Fasting) causesNoChange a(CHEBI:irinotecan)

Fasting protected against irinotecan-induced side effects without interfering with its anti-tumour efficacy. PubMed:26332723

Annotations
MeSH
Plasma
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

bp(MESHPP:Apoptosis) association a(CHEBI:irinotecan)

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

Annotations
MeSH
Colorectal Neoplasms

a(MESHC:"technetium 99m HYNIC-duramycin") positiveCorrelation a(CHEBI:irinotecan)

In vivo, (99m)Tc-duramycin uptake in COLO205 xenografts was increased 2.3- and 2.8-fold (P < 0.001) in mice treated with irinotecan and combination therapy, respectively. PubMed:26837335

Annotations
Disease Ontology (DO)
colorectal cancer

path(MESHD:Leukopenia) association a(CHEBI:irinotecan)

Ad libitum fed animals developed leucopenia compared with untreated controls, whereas fasted mice did not. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

p(HGNC:AKT1) association a(CHEBI:irinotecan)

and sensitized them to pharmacological treatments with irinotecan, SN-38 and cetuximab (at least in part through a down-regulation of AKT). PubMed:25917796

Annotations
Experimental Factor Ontology (EFO)
Caco-2
Experimental Factor Ontology (EFO)
DLD-1 cell
Disease Ontology (DO)
colorectal cancer

p(HGNC:UBE3D) decreases a(CHEBI:irinotecan)

and sensitized them to pharmacological treatments with irinotecan, SN-38 and cetuximab (at least in part through a down-regulation of AKT). PubMed:25917796

Annotations
Experimental Factor Ontology (EFO)
Caco-2
Experimental Factor Ontology (EFO)
DLD-1 cell
Disease Ontology (DO)
colorectal cancer

Out-Edges 67

a(CHEBI:irinotecan) positiveCorrelation path(MESHD:Leukopenia)

Ad libitum fed animals developed leucopenia compared with untreated controls, whereas fasted mice did not. PubMed:26332723

a(CHEBI:irinotecan) increases path(MESHD:Neutropenia)

The main limitation to the use of irinotecan in the treatment of colorectal cancer is the severity of side effects, including neutropaenia and diarrhoea. PubMed:26332723

a(CHEBI:irinotecan) decreases path(MESHD:"Colorectal Neoplasms")

irinotecan suppressed tumour growth equally in both treated groups, compared with untreated controls. PubMed:26332723

a(CHEBI:irinotecan) increases path(MESHD:Diarrhea)

The main limitation to the use of irinotecan in the treatment of colorectal cancer is the severity of side effects, including neutropaenia and diarrhoea. PubMed:26332723

a(CHEBI:irinotecan) increases path(MESHD:Diarrhea)

Fasting prevented the diarrhoea and visible signs of discomfort induced by irinotecan. PubMed:26332723

a(CHEBI:irinotecan) decreases bp(GOBP:"cell growth")

irinotecan suppressed tumour growth equally in both treated groups, compared with untreated controls. PubMed:26332723

a(CHEBI:irinotecan) decreases bp(GOBP:"cell growth")

Fasting protected against irinotecan-induced side effects without interfering with its anti-tumour efficacy. PubMed:26332723

a(CHEBI:irinotecan) decreases path(MESHD:Neoplasms)

We have previously shown that 5-methylselenocysteine (MSC) enhances therapeutic efficacy of irinotecan in various human tumor xenografts. PubMed:19632930

Annotations
Experimental Factor Ontology (EFO)
MDAMB435
MeSH
Intracellular Space
MeSH
Neoplasms
Evidence and Conclusion Ontology
western blot
MeSH
Heterografts
NCBI Taxonomy Names
Homo sapiens
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) increases a(SCHEM:"SN 38")

Irinotecan is one of the main treatments of colorectal cancer; it is converted into its active metabolite SN38 and acts as a topoisomerase I inhibitor. PubMed:25436684

Annotations
Experimental Factor Ontology (EFO)
COLO205
MeSH
Chromatin
MeSH
Colorectal Neoplasms
Evidence and Conclusion Ontology
western blot
MeSH
Allografts
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) positiveCorrelation a(MESHC:"technetium 99m HYNIC-duramycin")

In vivo, (99m)Tc-duramycin uptake in COLO205 xenografts was increased 2.3- and 2.8-fold (P < 0.001) in mice treated with irinotecan and combination therapy, respectively. PubMed:26837335

Annotations
Experimental Factor Ontology (EFO)
HCT-15 cell
MeSH
Intracellular Space
MeSH
Condylomata Acuminata
MeSH
Mucus
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

a(CHEBI:irinotecan) association bp(GOBP:"negative regulation of hepatocyte growth factor receptor signaling pathway")

We determined secreted HGF in fibroblast conditioned medium (CM). Combination treatment of anti-HGF antibody and irinotecan (CPT-11) directly enhanced CPT-11 sensitivity in CRC PubMed:26090722

Annotations
Experimental Factor Ontology (EFO)
HT-29
Experimental Factor Ontology (EFO)
DLD1
MeSH
Intracellular Space
MeSH
Gastrointestinal Neoplasms
MeSH
Mucus
NCBI Taxonomy Names
Crataegus azarolus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

a(CHEBI:irinotecan) increases path(MESHD:Diarrhea)

The main limitation to the use of irinotecan in the treatment of colorectal cancer is the severity of side effects, including neutropaenia and diarrhoea. PubMed:26332723

Annotations
Experimental Factor Ontology (EFO)
LS174T
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Peritoneum
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) increases path(MESHD:Diarrhea)

Fasting prevented the diarrhoea and visible signs of discomfort induced by irinotecan. PubMed:26332723

Annotations
Experimental Factor Ontology (EFO)
LS174T
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Peritoneum
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association path(MESHD:Leukopenia)

Ad libitum fed animals developed leucopenia compared with untreated controls, whereas fasted mice did not. PubMed:26332723

Annotations
Experimental Factor Ontology (EFO)
LS174T
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Peritoneum
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association p(HGNC:AKT1)

and sensitized them to pharmacological treatments with irinotecan, SN-38 and cetuximab (at least in part through a down-regulation of AKT). PubMed:25917796

Annotations
Experimental Factor Ontology (EFO)
Caco-2
Experimental Factor Ontology (EFO)
DLD-1 cell
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Plasma
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) decreases bp(GOBP:"cell growth")

irinotecan suppressed tumour growth equally in both treated groups, compared with untreated controls. PubMed:26332723

Annotations
Experimental Factor Ontology (EFO)
LS174T
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Peritoneum
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) decreases bp(GOBP:"cell growth")

Fasting protected against irinotecan-induced side effects without interfering with its anti-tumour efficacy. PubMed:26332723

Annotations
Experimental Factor Ontology (EFO)
LS174T
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Plasma
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association g(HGNC:UGT1A1)

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

a(CHEBI:irinotecan) decreases path(MESHD:"Colorectal Neoplasms")

Although monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) have largely enriched the available therapeutic choices for colorectal cancer (CRC), the understanding and management of their associated clinical toxicities are limited. In addition, the combined strategies of administering EGFR mAbs and traditional cytotoxic agents, such as 5-fluorouracil, oxaliplatin and irinotecan, have resulted in a more complicated management of CRC treatment-related side effects compared with EGFR mAb monotherapy. We believe that a thorough recognition of the toxicities of EGFR mAb drugs is essential for physicians to increase the therapeutic index in the treatment of CRC. PubMed:27340349

a(CHEBI:irinotecan) decreases path(MESHD:"Colorectal Neoplasms")

irinotecan suppressed tumour growth equally in both treated groups, compared with untreated controls. PubMed:26332723

Annotations
Experimental Factor Ontology (EFO)
LS174T
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Peritoneum
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association path(MESHD:"Colorectal Neoplasms")

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

Annotations
Experimental Factor Ontology (EFO)
COLO205
MeSH
Chromatin
MeSH
Colorectal Neoplasms
Evidence and Conclusion Ontology
western blot
MeSH
Allografts
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association p(HGNC:ACLY)

We conclude that targeting ACLy may improve the therapeutic effects of irinotecan and that simultaneous targeting of ACLy and AKT may be warranted to overcome SN38 resistance. PubMed:24132143

Annotations
Experimental Factor Ontology (EFO)
cancer cell line
MeSH
Microtubules
MeSH
Colorectal Neoplasms
Evidence and Conclusion Ontology
RNAi
MeSH
Heterografts
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association bp(MESHPP:"DNA Breaks, Double-Stranded")

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

Annotations
Experimental Factor Ontology (EFO)
COLO205
MeSH
Chromatin
MeSH
Colorectal Neoplasms
Evidence and Conclusion Ontology
western blot
MeSH
Allografts
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) increases path(MESHD:Neutropenia)

The main limitation to the use of irinotecan in the treatment of colorectal cancer is the severity of side effects, including neutropaenia and diarrhoea. PubMed:26332723

Annotations
Experimental Factor Ontology (EFO)
LS174T
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Peritoneum
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association p(HGNC:ABCB1)

Furthermore, miR-451 restoration decreases expression of the ATP-binding cassette drug transporter ABCB1 and results in irinotecan sensitization. PubMed:21948564

Annotations
Experimental Factor Ontology (EFO)
HCT116
MeSH
Peroxisomes
MeSH
Colorectal Neoplasms
Evidence and Conclusion Ontology
immunohistochemistry
Evidence and Conclusion Ontology
protein expression
MeSH
Macrophages
NCBI Taxonomy Names
Homo sapiens
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association bp(GOBP:"apoptotic process")

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

Annotations
Experimental Factor Ontology (EFO)
COLO205
MeSH
Chromatin
MeSH
Colorectal Neoplasms
Evidence and Conclusion Ontology
western blot
MeSH
Allografts
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association bp(MESHPP:"Drug Resistance")

Primary and metastatic tumors expressing EDR to 5FU + FA demonstrated up to 58% cross-resistance to a variety of chemotherapy agents, with the lowest percentages for oxaliplatin (11% and 8%, respectively) and irinotecan (16% and 14%). PubMed:20695724

Annotations
Experimental Factor Ontology (EFO)
HeLa cell
MeSH
Intracellular Space
MeSH
Neoplasms
Evidence and Conclusion Ontology
RNAi
MeSH
Colon
NCBI Taxonomy Names
Rattus norvegicus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) increases a(CHEBI:"SN-38")

Levels of the active irinotecan metabolite SN-38 9 (calculated as AUC values) were significantly lower in fasted mice in both plasma and liver, but not in tumour tissue. PubMed:26332723

Annotations
Experimental Factor Ontology (EFO)
LS174T
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Liver
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) increases a(CHEBI:"SN-38")

Levels of the active irinotecan metabolite SN-38 9 (calculated as AUC values) were significantly lower in fasted mice in both plasma and liver, but not in tumour tissue. PubMed:26332723

Annotations
Experimental Factor Ontology (EFO)
LS174T
MeSH
Intracellular Space
MeSH
Neoplasm Metastasis
MeSH
Plasma
NCBI Taxonomy Names
Atractylodes macrocephala
NCBI Taxonomy Names
Panax ginseng
NCBI Taxonomy Names
Astragalus membranaceus
NCBI Taxonomy Names
Glycyrrhiza uralensis
NCBI Taxonomy Names
Poria cocos
NCBI Taxonomy Names
Coix lacryma-jobi
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) decreases path(MESHD:Neoplasms)

We have previously shown that 5-methylselenocysteine (MSC) enhances therapeutic efficacy of irinotecan in various human tumor xenografts. PubMed:19632930

a(CHEBI:irinotecan) increases a(SCHEM:"SN 38")

Irinotecan is one of the main treatments of colorectal cancer; it is converted into its active metabolite SN38 and acts as a topoisomerase I inhibitor. PubMed:25436684

a(CHEBI:irinotecan) positiveCorrelation a(MESHC:"technetium 99m HYNIC-duramycin")

In vivo, (99m)Tc-duramycin uptake in COLO205 xenografts was increased 2.3- and 2.8-fold (P < 0.001) in mice treated with irinotecan and combination therapy, respectively. PubMed:26837335

a(CHEBI:irinotecan) association bp(GOBP:"negative regulation of hepatocyte growth factor receptor signaling pathway")

We determined secreted HGF in fibroblast conditioned medium (CM). Combination treatment of anti-HGF antibody and irinotecan (CPT-11) directly enhanced CPT-11 sensitivity in CRC PubMed:26090722

a(CHEBI:irinotecan) increases path(MESHD:Diarrhea)

The main limitation to the use of irinotecan in the treatment of colorectal cancer is the severity of side effects, including neutropaenia and diarrhoea. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) increases path(MESHD:Diarrhea)

Fasting prevented the diarrhoea and visible signs of discomfort induced by irinotecan. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association path(MESHD:Leukopenia)

Ad libitum fed animals developed leucopenia compared with untreated controls, whereas fasted mice did not. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association p(HGNC:AKT1)

and sensitized them to pharmacological treatments with irinotecan, SN-38 and cetuximab (at least in part through a down-regulation of AKT). PubMed:25917796

Annotations
Experimental Factor Ontology (EFO)
Caco-2
Experimental Factor Ontology (EFO)
DLD-1 cell
Disease Ontology (DO)
colorectal cancer

a(CHEBI:irinotecan) decreases bp(GOBP:"cell growth")

irinotecan suppressed tumour growth equally in both treated groups, compared with untreated controls. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) decreases bp(GOBP:"cell growth")

Fasting protected against irinotecan-induced side effects without interfering with its anti-tumour efficacy. PubMed:26332723

Annotations
MeSH
Plasma
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association g(HGNC:UGT1A1)

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

a(CHEBI:irinotecan) decreases path(MESHD:"Colorectal Neoplasms")

Although monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) have largely enriched the available therapeutic choices for colorectal cancer (CRC), the understanding and management of their associated clinical toxicities are limited. In addition, the combined strategies of administering EGFR mAbs and traditional cytotoxic agents, such as 5-fluorouracil, oxaliplatin and irinotecan, have resulted in a more complicated management of CRC treatment-related side effects compared with EGFR mAb monotherapy. We believe that a thorough recognition of the toxicities of EGFR mAb drugs is essential for physicians to increase the therapeutic index in the treatment of CRC. PubMed:27340349

a(CHEBI:irinotecan) decreases path(MESHD:"Colorectal Neoplasms")

irinotecan suppressed tumour growth equally in both treated groups, compared with untreated controls. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association path(MESHD:"Colorectal Neoplasms")

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

a(CHEBI:irinotecan) association p(HGNC:ACLY)

We conclude that targeting ACLy may improve the therapeutic effects of irinotecan and that simultaneous targeting of ACLy and AKT may be warranted to overcome SN38 resistance. PubMed:24132143

a(CHEBI:irinotecan) association bp(MESHPP:"DNA Breaks, Double-Stranded")

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

a(CHEBI:irinotecan) increases path(MESHD:Neutropenia)

The main limitation to the use of irinotecan in the treatment of colorectal cancer is the severity of side effects, including neutropaenia and diarrhoea. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association p(HGNC:ABCB1)

Furthermore, miR-451 restoration decreases expression of the ATP-binding cassette drug transporter ABCB1 and results in irinotecan sensitization. PubMed:21948564

a(CHEBI:irinotecan) association bp(GOBP:"apoptotic process")

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

a(CHEBI:irinotecan) association bp(MESHPP:"Drug Resistance")

Primary and metastatic tumors expressing EDR to 5FU + FA demonstrated up to 58% cross-resistance to a variety of chemotherapy agents, with the lowest percentages for oxaliplatin (11% and 8%, respectively) and irinotecan (16% and 14%). PubMed:20695724

a(CHEBI:irinotecan) increases a(CHEBI:"SN-38")

Levels of the active irinotecan metabolite SN-38 9 (calculated as AUC values) were significantly lower in fasted mice in both plasma and liver, but not in tumour tissue. PubMed:26332723

Annotations
MeSH
Liver
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) increases a(CHEBI:"SN-38")

Levels of the active irinotecan metabolite SN-38 9 (calculated as AUC values) were significantly lower in fasted mice in both plasma and liver, but not in tumour tissue. PubMed:26332723

Annotations
MeSH
Plasma
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) positiveCorrelation a(MESHC:"technetium 99m HYNIC-duramycin")

In vivo, (99m)Tc-duramycin uptake in COLO205 xenografts was increased 2.3- and 2.8-fold (P < 0.001) in mice treated with irinotecan and combination therapy, respectively. PubMed:26837335

Annotations
Disease Ontology (DO)
colorectal cancer

a(CHEBI:irinotecan) increases path(MESHD:Diarrhea)

The main limitation to the use of irinotecan in the treatment of colorectal cancer is the severity of side effects, including neutropaenia and diarrhoea. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) increases path(MESHD:Diarrhea)

Fasting prevented the diarrhoea and visible signs of discomfort induced by irinotecan. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association bp(MESHPP:Apoptosis)

The treatment of colorectal cancer cells with irinotecan leads to senescence or apoptosis following DNA double-strand break induction. PubMed:25436684

Annotations
MeSH
Colorectal Neoplasms

a(CHEBI:irinotecan) association path(MESHD:Leukopenia)

Ad libitum fed animals developed leucopenia compared with untreated controls, whereas fasted mice did not. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association p(HGNC:AKT1)

and sensitized them to pharmacological treatments with irinotecan, SN-38 and cetuximab (at least in part through a down-regulation of AKT). PubMed:25917796

Annotations
Experimental Factor Ontology (EFO)
Caco-2
Experimental Factor Ontology (EFO)
DLD-1 cell
Disease Ontology (DO)
colorectal cancer

a(CHEBI:irinotecan) decreases bp(GOBP:"cell growth")

irinotecan suppressed tumour growth equally in both treated groups, compared with untreated controls. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) decreases bp(GOBP:"cell growth")

Fasting protected against irinotecan-induced side effects without interfering with its anti-tumour efficacy. PubMed:26332723

Annotations
MeSH
Plasma
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) association g(HGNC:UGT1A1)

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

a(CHEBI:irinotecan) decreases path(MESHD:"Colorectal Neoplasms")

irinotecan suppressed tumour growth equally in both treated groups, compared with untreated controls. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) increases path(MESHD:Neutropenia)

The main limitation to the use of irinotecan in the treatment of colorectal cancer is the severity of side effects, including neutropaenia and diarrhoea. PubMed:26332723

Annotations
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) increases a(CHEBI:"SN-38")

Levels of the active irinotecan metabolite SN-38 9 (calculated as AUC values) were significantly lower in fasted mice in both plasma and liver, but not in tumour tissue. PubMed:26332723

Annotations
MeSH
Liver
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) increases a(CHEBI:"SN-38")

Levels of the active irinotecan metabolite SN-38 9 (calculated as AUC values) were significantly lower in fasted mice in both plasma and liver, but not in tumour tissue. PubMed:26332723

Annotations
MeSH
Plasma
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
10090

a(CHEBI:irinotecan) increases a(CHEBI:"SN-38")

Irinotecan is one of the main treatments of colorectal cancer; it is converted into its active metabolite SN38 and acts as a topoisomerase I inhibitor. PubMed:25436684

Annotations
MeSH
Colorectal Neoplasms

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of the open source project, PyBEL. Please feel free to contact us here to give us feedback or report any issues.